Evidence map›Paper›PMID 26215403›Full record

ArticleJournal of ovarian research2015

Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.

Andrew J Wilson, Jeanette Saskowski, Whitney Barham, Fiona Yull, Dineo Khabele

Open access · goldAbstract read
In one paragraph

Article in Journal of ovarian research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Thymoquinone, as a Novel Therapeutic Candidate of Cancers.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  12. Nutritional Value and Preventive Role ofMolecules (Basel, Switzerland) · 2021
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andrew J WilsonDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA. andrew.j.wilson@vanderbilt.edu.
Jeanette SaskowskiDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Whitney BarhamDepartment of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
Fiona YullDepartment of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA.
Dineo KhabeleDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Vanderbilt University School of Medicine, Nashville, TN, USA.
Vanderbilt University · USVanderbilt University Medical Center · US

Funding

Epithelial NF-KappaB signaling in Mammary TumorigenesisR01CA113734 · NCI · VANDERBILT UNIVERSITY · PI YULL, FIONA E · 2007 to 2011
$1.4M
Targeting Histone Deacetylases with Small Moleule Inhibitors in Ovarian CancerK08CA148887 · NCI · VANDERBILT UNIVERSITY · PI KHABELE, DINEO · 2010 to 2014
$795k
NCI NIH HHS K08 CA148887NCI NIH HHS K08CA148887NCI NIH HHS R01 CA113734NCI NIH HHS R01CA113734
6 · The paper itself

Abstract

backgroundOvarian cancer is the most lethal gynecologic malignancy characterized by the frequent development of resistance to platinum chemotherapy. Finding new drug combinations to overcome platinum resistance is a key clinical challenge. Thymoquinone (TQ) is a component of black seed oil that exerts multiple anti-tumorigenic effects on cells, including inhibition of NF-κB and promotion of DNA damage. We aimed to determine whether TQ enhances cisplatin cytotoxicity in cultured ovarian cancer cells and in an established murine syngeneic model of ovarian cancer.

methodsOvarian cancer cell viability in vitro was measured by sulforhodamine B (SRB) assays, and drug interactions tested for synergism by isobologram analysis. ID8-NGL mouse ovarian cancer cells stably expressing an NF-κB reporter transgene were injected intra-peritoneally into C57BL/6 mice. After 30 day TQ and/or cisplatin treatment, we measured the following indices: tumor burden (ascites volume, number of peritoneal implants and mesenteric tumor mass); NF-κB reporter activity (luciferase assay); protein expression of the double-strand DNA break marker, pH2AX(ser139), the proliferation markers, Ki67/mib-1 and PCNA, and the apoptosis markers, cleaved caspase-3, cleaved PARP and Bax; and mRNA expression of NF-κB targets, TNF-α and IL-1β. Two-tailed Mann-Whitney tests were used for measuring differences between groups in mouse experiments.

resultsIn SRB assays, TQ and cisplatin synergized in ID8-NGL cells. In mice, cisplatin significantly reduced cell proliferation and increased apoptosis in tumors, resulting in decreased overall tumor burden. Combining TQ with cisplatin further decreased these indices, indicating co-operative effects between the drugs. TQ treatment promoted cisplatin-induced pH2AX expression in cultured cells and in tumors. While NF-κB inhibition by TQ induced anti-tumor effects in vitro, we made the unexpected observation that TQ alone increased both tumor NF-κB activity and formation of ascites in vivo.

conclusionsTQ enhanced cisplatin-mediated cytoxicity in ovarian cancer cells in vitro and in a mouse syngeneic model, effects associated with increased DNA damage. However, our results strongly caution that TQ treatment alone may have an overall deleterious effect in the immunocompetent host through stimulation of ascites. Since TQ is a potential candidate for future clinical trials in ovarian cancer patients, this finding has considerable potential relevance to the clinic.

Indexed as

AnimalsApoptosisBenzoquinonesCaspase 3Cell Line, TumorCell ProliferationCell SurvivalCisplatinDisease Models, AnimalFemaleGene Expression Regulation, NeoplasticHumansMiceNF-kappa BOvarian NeoplasmsTumor Necrosis Factor-alphaBenzoquinonesCaspase 3CisplatinNF-kappa BthymoquinoneTumor Necrosis Factor-alpha

Identifiers

PMID26215403
PMCPMC4517540
OpenAlexW2168310809

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.